We are the creator of Viaskin®

We are a clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®.

Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT®, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin®.

DBV Technologies is advancing this unique technology to improve the lives of infants and children suffering from food allergies.